ClinicalTrials.gg
CompletedNCT05255276Updated May 8, 2024

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

A Phase 1 interventional study of Sitravatinib 50 mg and Sitravatinib 100 mg in Healthy Adults, sponsored by Mirati Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigate the Effect of P glycoprotein Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Healthy Subjects.

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Mirati Therapeutics Inc. is the lead sponsor of 51 studies on the registry; 3 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 4 (20%) have results posted.

First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • between 18.0 and 32.0 kg/m2, inclusive.
  • In good health, determined by no findings from medical history, physical examination, 12 lead , vital sign measurements, and clinical laboratory evaluations at screening and/or check-in, as assessed by the investigator (or qualified designee).
  • Females of will not be pregnant or lactating and must have a negative result on an approved pregnancy test at screening and check-in. Females of childbearing potential must agree to use .
  • Male subjects must agree to use contraception.
  • Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Key Exclusion Criteria:

  • Significant history of clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator.
  • History of significant , intolerance, or allergy to any drug compound, food, any components of the IMP, or other substance (not including seasonal allergies), unless approved by the investigator.
  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications. (Uncomplicated appendectomy and hernia repair are allowed. Cholecystectomy is not allowed.)
  • History of Gilbert's syndrome or suspicion of Gilbert's syndrome based on elevated total and indirect (may be confirmed by repeat).
  • Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to study drug administration on Day 1 of Period 1.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Group 1 Treatment A

    A single-dose administration of sitravatinib malate 50 mg on Day 1. Day 12, a single dose of sitravatinib malate 50 mg will be will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.

    Drug: Sitravatinib 50 mg

  • Active comparator
    Group 1 Treatment B

    On Days 9 to 11, itraconazole 200 mg will be administered QD in the morning. On Day 12, a single dose of sitravatinib malate 50 mg will be coadministered with itraconazole. Itraconazole QD dosing will continue on Days 13 to 18 to maintain steady state during the PK sample collection period.

    Drug: Itraconazole

  • Active comparator
    Group 2 Treatment A

    A single-dose administration of sitravatinib malate 100 mg on Day 1 will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.

    Drug: Sitravatinib 100 mg

  • Active comparator
    Group 2 Treatment B

    On Days 9 to 15, rifampin 600 mg will be administered QD in the morning. On Day 16, a single dose of sitravatinib malate 100 mg will be coadministered with rifampin followed by a 72 hour PK sample collection period. Rifampin QD dosing will continue on Days 17 to 22 to maintain steady state during the PK sample collection period.

    Drug: Rifampin

Interventions

  • 50 mg Sitravatinib on Day 1 (Group 1A)

    Also known as: MGCD516

  • 100 mg Sitravatinib on Day 1 (Group 2A)

    Also known as: MGCD516

  • Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)

    Also known as: Protonix

  • Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)

    Also known as: Pepcid

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - Cmax (sitravatinib)

    Maximum observed plasma concentration

    Time frame: Up to Day 168 hours after dosing

  2. Pharmacokinetics - AUC∞ (sitravatinib)

    Area under the plasma concentration-time curve from time zero extrapolated to infinity

    Time frame: Up to 168 hours after dosing

  3. Pharmacokinetics - AUClast (sitravatinib)

    Area under the curve from time zero to the last measured time point

    Time frame: Up to 168 hours after dosing

  4. Pharmacokinetics - tmax (sitravatinib)

    Terminal elimination half-life

    Time frame: Up to 168 hours after dosing

  5. Pharmacokinetics - CL/F (sitravatinib)

    Apparent total plasma clearance when dosed orally

    Time frame: Up to 168 hours after dosing

  6. Pharmacokinetics - Vz/F (sitravatinib)

    Apparent volume of distribution when dosed orally

    Time frame: Up to 168 hours after dosing

  7. Pharmacokinetics - uf (sitravatinib)

    Unbound fraction

    Time frame: Up to 168 hours after dosing

Secondary outcomes

  1. Adverse Events (AEs)

    Incidence and severity of AEs

    Time frame: Up to 12 weeks from screening

07

Study locations

1 site
  • Labcorp Drug Development Clinical Research Unit
    Dallas, Texas 75247, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in May 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Feb 24, 2022
StartActual
Feb 2, 2022
Primary completionActual
May 12, 2022
CompletionActual
Feb 10, 2023
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05255276
Responsible party
Sponsor
First posted
Feb 24, 2022
Start date
Feb 2, 2022
Primary completion
May 12, 2022
Completion
Feb 10, 2023
Last update
May 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitravatinib · Itraconazole · Rifampin

Start the discussion